WuXi AppTec, one of the world’s largest contract drug developers and manufacturers and an important producer of peptides, is off the Pentagon’s list of Chinese military companies. The U.S. Department of Defense removed it on November 9, 2026, after a federal judge found in August that the government’s designation was likely arbitrary and capricious. The removal was published in the Federal Register the following day. WuXi’s Hong Kong shares rose as much as 6% on Tuesday morning.
But the victory comes with a catch. The Pentagon expressly reserved the right to put WuXi AppTec back on the list using additional or supplementary grounds. Meanwhile, a separate deadline under the BIOSECURE Act is approaching: the White House Office of Management and Budget, or OMB, is required to publish its initial list of biotechnology companies of concern by December 18, 2026.
Getting off the Pentagon’s list removes one route to a BIOSECURE designation for now. It does not eliminate the other.
For the peptide and GLP-1 supply chain, this is not a niche trade dispute. WuXi’s TIDES business manufactures oligonucleotides and peptides, and its manufacturing capacity has expanded rapidly as drug developers have pursued increasingly complex medicines. Whether U.S. biotech sponsors can continue relying on Chinese manufacturing, or need to move programs elsewhere, has been an open question for more than two years.
The legal result is real. So is the uncertainty it leaves behind.
How WuXi AppTec Landed on the 1260H List
The 1260H list takes its name from a section of the fiscal 2021 National Defense Authorization Act. It identifies companies the Department of Defense considers Chinese military companies operating in the United States. The designation can trigger federal procurement restrictions and substantial commercial consequences.
WuXi AppTec’s scrutiny preceded its listing. In February 2024, a bipartisan group of lawmakers, including Senator Bill Hagerty and Senator Gary Peters, urged federal agencies to investigate the company over alleged connections to China’s military and government. WuXi has consistently rejected allegations that it operates as a Chinese military company.
On June 8, 2026, the Pentagon added WuXi AppTec to an updated 1260H list. The government published the list in the Federal Register on June 10.
WuXi went to court almost immediately. On June 11, the company filed suit in the U.S. District Court for the District of Columbia, arguing that the designation lacked factual support and violated the Administrative Procedure Act. It requested a preliminary injunction on June 29, and the court heard arguments on July 22.
The litigation was not simply about whether WuXi could sell services directly to the Pentagon. A military-company designation could also influence federal contractors, publicly funded biotechnology programs, and private pharmaceutical companies concerned about future restrictions.
The market did not wait for a final judgment. According to the court’s subsequent opinion, customers began pausing collaborations, canceling projects and redirecting work to competitors.
WuXi challenged a government designation. Its customers were already making supply-chain decisions.
Why the Court Sided With WuXi
On August 7, Chief Judge James Boasberg granted the company’s request for a preliminary injunction, preventing the Defense Department from enforcing or giving effect to the designation while the litigation continues.
The court found that WuXi was likely to succeed on its argument that the government’s decision was arbitrary and capricious. The problem was not that the Pentagon lacked the authority to investigate potential military connections. It was that the evidence it cited did not support the conclusions it drew.
One example involved a Chinese investment fund associated with Aviation Industry Corporation of China, or AVIC. The government’s analysis treated a reported 5.32% holding as though the fund owned that percentage of WuXi AppTec.
But the figure described something different: WuXi shares represented 5.32% of the fund’s portfolio. It was a measure of how the fund invested its assets, not how much of WuXi the fund controlled.
WuXi calculated that the position represented approximately 0.001% of its equity. The judge did not need to adopt that calculation to find the Pentagon’s interpretation defective. A fund allocating part of its portfolio to a stock is not the same as owning an equivalent percentage of the company issuing that stock.
The court also questioned evidence used to connect WuXi with Chinese defense-related research institutions. Records describing the company as a third-party laboratory had been interpreted as evidence of research partnerships or military affiliations that the documents did not establish.
The court’s conclusion was procedural and evidentiary, not a permanent declaration that WuXi could never qualify for designation. The Pentagon remains able to attempt a new listing if it relies on a different, adequately supported justification.
The court also found that the consequences were immediate and difficult to reverse. Customers had paused or moved research programs, suppliers had suspended shipments, and some commercial relationships appeared unlikely to return even if WuXi ultimately won the case.
The judge identified a government evidence problem. The company’s customers had already identified a business risk.
On November 9, WuXi learned that the Defense Department had decided to remove the company. The Federal Register notice published November 10 confirmed the delisting and stated that it was made in compliance with the August 7 injunction.
The official notice also made clear that the government could relist WuXi using additional or supplementary grounds. The litigation was not converted into a final decision on the merits by the administrative removal.
The BIOSECURE Act Clock Keeps Running
The BIOSECURE Act became law on December 18, 2025, as Section 851 of the fiscal 2026 National Defense Authorization Act. It restricts specified federal procurement, contracting and funding relationships involving biotechnology companies designated as companies of concern.
The law does not simply ban all private business with a named manufacturer. Its central restrictions concern federal agencies buying services from designated companies, and certain federal contractors or funding recipients using those services to perform government-funded work.
That distinction matters. The legal restrictions are narrower than a universal prohibition on commercial purchases. Their consequences can nevertheless spread through private pharmaceutical supply chains when customers anticipate compliance problems, future government funding needs or reputational exposure.
BIOSECURE creates two main routes to designation as a biotechnology company of concern.
The first is linked to the Pentagon’s Section 1260H list. A company appearing on that list and meeting the statutory biotechnology criteria can qualify for designation through that route.
The second does not depend on a 1260H listing. OMB can designate a biotechnology company under separate criteria involving foreign-adversary government control or direction, biotechnology activity and national security risk. The process includes notice and an opportunity to challenge a proposed designation.
WuXi’s November removal closes the first route unless the Pentagon successfully redesignates it. It does not prevent OMB from considering the company under the second.
According to the statute, OMB must publish its initial list of biotechnology companies of concern by December 18, 2026. That deadline is the immediate event for pharmaceutical sponsors to watch.
Getting off the Pentagon list closes one door. The OMB process leaves another open.
There is a second timeline worth separating from the first. Existing Defense Department procurement restrictions tied to the 1260H framework have June 30, 2026 and June 30, 2027 statutory effective dates for different types of procurement.
The broader BIOSECURE Act prohibitions follow a different implementation sequence. OMB’s initial list comes first. The agency then has 180 days after publication to issue implementing guidance, and the Federal Acquisition Regulatory Council has up to one year after that guidance to revise federal procurement regulations.
For companies designated through the 1260H-linked route, the BIOSECURE prohibitions become effective 60 days after the relevant procurement regulations are revised. For other designated companies, the interval is 90 days. Legal analyses place the resulting implementation horizon around August or September 2028 if agencies use the maximum statutory periods.
The statute also includes a five-year grandfathering provision for certain existing contractual arrangements, tied to the procurement-rule revision date. Its application depends on the statutory conditions and the contracts involved.
In other words, December 18 is a designation deadline, not the day every affected drugmaker must shut down an existing manufacturing arrangement. But a decision made in December could influence contracts years before the full restrictions become effective.
Why WuXi AppTec Matters to the Peptide Supply Chain
WuXi’s scale is the reason this dispute matters far beyond one Chinese company’s share price.
On October 26, WuXi AppTec reported revenue of RMB 45.54 billion for the first nine months of 2026, up 38.6% from the corresponding period a year earlier. Adjusted non-IFRS net profit increased 74.4% to RMB 18.38 billion, while the backlog for continuing operations reached RMB 76.74 billion, up 36.4%.
The company raised its full-year revenue forecast to between RMB 61.0 billion and RMB 61.9 billion. These figures came from its unaudited third-quarter reporting and reflect the company’s own financial disclosures.
The growth is especially relevant to drugmakers developing peptides and oligonucleotides. WuXi’s TIDES business provides development and manufacturing services for both categories.
In the first nine months of 2025, TIDES generated RMB 7.84 billion in revenue, up 121.1% year on year. In its subsequent full-year results, WuXi reported that TIDES revenue for 2025 had reached RMB 11.37 billion, up 96.0%.
WuXi also reported that, following the completion of new capacity in Taixing in September 2025, its total solid-phase peptide synthesizer reactor volume exceeded 100,000 liters.
That capacity is commercially significant because manufacturing peptides at scale demands specialized equipment, validated processes, quality systems and the ability to transfer complex chemistry from laboratory development into reliable production.
Changing a contract manufacturer is not simply a matter of ordering the same ingredient from another factory. Depending on the product and its development stage, transferring processes can require new analytical comparisons, engineering work, additional validation and regulatory documentation.
In the August court ruling, WuXi presented evidence that a substantial share of its business depended on U.S. customers. The judge cited approximately 70% of revenue coming from those customers, helping explain why the designation produced immediate commercial harm.
Customers had paused collaborations, canceled prospective work, and in some cases redirected existing programs to other providers. The court treated those decisions as evidence that a later victory would not necessarily restore the business.
Western manufacturers have been investing in additional capacity as well. Grey Pepper has reported on Cambrex’s $120 million Iowa peptide-manufacturing expansion, one example of the push to increase production options outside China.
Washington has also been tightening other channels of technology investment involving China, as our coverage of the Treasury outbound investment rule for biotechnology examined.
For biotech sponsors, these developments do not necessarily mean every manufacturing program must leave China. They do mean that jurisdiction, funding exposure, contractual dependencies and the ability to qualify an alternative supplier have become part of supply-chain planning.
The question is no longer just who can make a peptide at the right specification and price. It is also where that manufacturing relationship might stand when the next regulatory deadline arrives.
What the Delisting Does Not Settle
Several questions remain unresolved.
The first is legal. The August injunction was preliminary, not a final judgment. The court found serious problems with the Pentagon’s supporting evidence but did not permanently prohibit the department from issuing a new designation.
The second concerns OMB. As of this reporting, there is no confirmed designation of WuXi AppTec through BIOSECURE’s independent pathway. Whether the agency will attempt one, and whether any resulting determination will withstand challenge, remains unknown.
The third is commercial. The court described lost and redirected business, but public disclosures reviewed by Grey Pepper do not establish how many manufacturing programs left WuXi because of the June listing or how many have returned after its removal.
Some customers may resume projects now that the immediate designation is gone. Others may have already committed to different manufacturers, or may be unwilling to reverse supply-chain decisions while the OMB deadline remains ahead.
That uncertainty creates an uncomfortable choice for drug sponsors: spend money qualifying alternative manufacturers before a definitive restriction exists, or keep existing programs in place while accepting the possibility of more disruption later.
For a company with commercial products, clinical trials and years of manufacturing work tied to one supplier, either decision can be expensive.
WuXi has won meaningful preliminary relief, and the Pentagon has removed it from the current list. Those are established facts. They do not resolve the larger question of how U.S. biotechnology procurement policy will treat Chinese contract manufacturers.
WuXi won this round in court. The next consequential deadline belongs to a budget office.
December 18 will not automatically settle every supply-chain question. But it could tell Western pharmaceutical companies whether this particular legal victory has opened a durable route forward, or merely bought WuXi more time.
Sources
- U.S. Department of Defense / Federal Register — Notice of Removal of Designated Chinese Military Company, November 10, 2026, 91 FR 72536.
- U.S. District Court for the District of Columbia — WuXi AppTec Co., Ltd. v. U.S. Department of Defense, Memorandum Opinion, August 7, 2026, Civil Action 26-2069.
- U.S. Congress / Government Publishing Office — Public Law 119-60, National Defense Authorization Act for Fiscal Year 2026, Section 851 (BIOSECURE Act), enacted December 18, 2025.
- Ropes & Gray — DoD Removes WuXi AppTec from the 1260H List, November 11, 2026.
- WuXi AppTec — Q1–Q3 2026 Financial Results and Updated Full-Year Guidance, October 26, 2026.
- WuXi AppTec — WuXi AppTec Beat Full-Year Guidance and Achieved Record Performance in 2025, 2026.
- Reuters — WuXi AppTec Removed from Pentagon List of Chinese Military Companies, November 10, 2026.
- Baker McKenzie — United States: The BIOSECURE Act Becomes Law, January 2026.
- Office of Senator Bill Hagerty — Bipartisan Lawmakers Call for Investigation of WuXi AppTec, February 12, 2024.
